Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial-Reference-Cited by-同舟云学术

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

Published:2024-03 Issue:3 Volume:5 Page:101435
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Larkin James,Marais Richard,Porta Nuria^ORCID,Gonzalez de Castro David,Parsons Lisa,Messiou Christina,Stamp Gordon,Thompson Lisa,Edmonds Kim,Sarker Sarah,Banerji Jane,Lorigan Paul,Evans Thomas R. Jeffry,Corrie Pippa,Marshall Ernest,Middleton Mark R.,Nathan Paul,Nicholson Steve,Ottensmeier Christian,Plummer Ruth,Bliss Judith,Valpione Sara,Turajlic Samra^ORCID

Funder

Novartis AG

Cancer Research UK

Publisher

Elsevier BV

Reference66 articles.

1. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis;D'Angelo;J. Clin. Oncol.,2017

2. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005;Bradford;Arch. Dermatol.,2009

3. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma;Furney;J. Pathol.,2013

4. Therapeutic implications of KIT in melanoma;Postow;Cancer J.,2012

5. Melanoma in Mexico: Clinicopathologic Features in a Population with Predominance of Acral Lentiginous Subtype;Lino-Silva;Ann. Surg Oncol.,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30

2. Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event;Cancers;2024-07-24

3. Curing Stage IV Melanoma: Where Have We Been and Where Are We?;American Society of Clinical Oncology Educational Book;2024-06